CN103893175A - Application of brompheniramine in preparation of medicine for treating or preventing influenza virus infection - Google Patents
Application of brompheniramine in preparation of medicine for treating or preventing influenza virus infection Download PDFInfo
- Publication number
- CN103893175A CN103893175A CN201410157329.9A CN201410157329A CN103893175A CN 103893175 A CN103893175 A CN 103893175A CN 201410157329 A CN201410157329 A CN 201410157329A CN 103893175 A CN103893175 A CN 103893175A
- Authority
- CN
- China
- Prior art keywords
- brompheniramine
- medicine
- virus
- influenza
- influenza virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to the technical field of medicines, and in particular discloses an application of brompheniramine in preparation of a medicine for treating or preventing influenza virus infection. Firstly, the toxicity of the brompheniramine to MDCK (Madin-Darby Canine Kidney) cells is detected, wherein the result shows that the brompheniramine is completely nontoxic to the cells within a measured concentration range; secondly, the antiviral activity of the brompheniramine is measured within a completely nontoxic concentration range, wherein the result shows that the brompheniramine is a small molecule compound with the obvious antiviral activity and the antiviral function of the brompheniramine is in a dose-dependent effect; and finally, the antiviral activity of the brompheniramine to different types and subtypes of influenza viruses is detected, wherein the result shows that the brompheniramine can be used for inhibiting the duplication of all detected influenza virus strains in a dose-dependent manner, so that the anti-influenza virus activity of the brompheniramine is broad-spectrum. Thus, the brompheniramine disclosed by the invention for the first time is a novel broad-spectrum anti-influenza virus medicine, which can be used for preparing the medicine for treating or preventing the influenza virus infection.
Description
Technical field
The present invention relates to medical technical field, be specifically related to the application of a kind of brompheniramine in preparation treatment or flu-prevention virus infective medicament.
Background technology
Influenza virus belongs to orthomyxoviridae family (Orthomyxoviridae), Influenza Virus.According to virion nucleoprotein (NP) and the antigenic characteristic of stromatin (M) and the difference of genetic characteristics, influenza virus is divided into A, B, C tri-types, also claims first, second, the third three types.The full genome of A type influenza virus is made up of 8 sub-thread strand RNAs that differ in size, and names respectively with sections 1 to sections 8.The about 13.6kb of viral genome total length, encode 10 kinds of structural protein (PB2, PB1, PA, HA, NP, NA, M1, M2, PB1-F2 and NS2/NEP) and non-structural protein (NS1).According to the difference of virion surface glycoprotein hemagglutinin (HA) and neuraminidase (NA), A type influenza virus can be further divided into 17 H (H1-H17) and 10 N (N1-N10) hypotype.Human influenza virus is mainly H1, H2 and H3 hypotype.Mostly be H5, H7 and H9 hypotype and endanger at present serious high pathogenic avian influenza, wherein the highest with the fatality rate of H5N1 hypotype.Type B influenza virus often causes influenza localized epidemics, does not cause worldwide influenza great outburst, only in people and sea dog, finds.C type influenza virus exists mainly with the form that is dispersed in, and mainly attacks infant, does not generally cause influenza pandemic, can infect the mankind and pig.
The whole biocycle of influenza virus need to complete in Cytoplasm and nucleus.Infect initial be the furcella HA identification on virion surface and in conjunction with host cell surface containing sialic receptor.The connecting key of sialic acid and time terminal galactose, has determined viral host specificity, and this connecting key is α (2-3) in birds, is α (2-6) in the mankind.After virus absorption onto cell, cell is taken in virus by the receptor-mediated pinocytosis of clathrin.In cell, clathrin molecular dissociation, virus merges and forms phagosome with endosome, makes virion pH value around drop to 5.0 left and right.Under this pH condition, the conformation of viral HA albumen changes, and the fusogenic peptide that is positioned at light chain (HA2) N end is exposed, thereby causes that virus envelope and cell membrane merge.Low pH environment also causes a large amount of H
+enter virion inside via M2 ion channel, cause dissociating of M1 albumen and vRNPs.Both common results cause the vRNPs of virion to be discharged into the endochylema of infected cell.VRNPs forwards to subsequently and in nucleus, carries out genomicly copying and transcribing, and while copying, virus is first take self RNA as template synthesize complementary rna (cRNA), then take cRNA as template resynthesis vRNA.Transcribe the mRNA of generation by transferring to endochylema in core, translate viral structural protein and non-structural protein.Part synthetic proteins is assembled into vRNP as NP need to transfer in core again with newly-generated vRNA, vRNP starts to be assembled into new virion with remaining virus protein after going out core, newly-generated progeny virus is by the glycoprotein of neuraminidase (NA) hydrolysis cell surface, discharge N-acetyl-neuraminate, impel virion to discharge from the site of sprouting.The final step of virus maturation is that HA is cracked into HA1 and HA2 polypeptide under the effect of host protein enzyme, and such virion just has infectivity, thereby starts copying of new round virus.
Influenza virus has been caused in the world and has been very popular for five times since 20 beginnings of the century were found, about 10 years, can produce an outbreak of epidemic, has caused in the world huge loss.Influenza pandemic can cause 250,000～500,000 examples dead every year, 3,000,000～5,000,000 severe disease examples, and it is infected that the whole world approximately has 5～15% people.Vaccination and use antiviral drugs are the important means of reply flu outbreak, but because influenza antigen variation ability is strong, substantially can not large-scale production vaccine before being very popular.At present, there are two classes through the anti-influenza virus medicament of food and drug administration (FDA) approval official listing: (1) M2 ion channel blocking agent take amantadine and rimantadine as representative.This type of medicine only has preventive and therapeutic action to influenza A virus, and research shows that this type of medicine has the toxic and side effects such as neurotoxicity, and due to the ubiquity of persister, so CDC advises that this type of medicine is not used further to flu-prevention viral infection.(2) neuraminidase inhibitor, the representative of this type of medicine is oseltamivir and Zha La meter Wei.This type of medicine is all effective to all known human influenza viruses and high pathogenic avian influenza virus.But really constantly there is report about oseltamivir persister in recent years.Therefore, research development of new anti-influenza virus medicament are significant.
Brompheniramine (Brompheniramine), has another name called Brompheniramine or brompheniramine, chemistry N by name, N-dimethyl-gamma-(4-bromophenyl)-2-pyridine propylamine maleate.Its esters brompheniramine maleate (Brompheniramine maleate) is usually used in medicine.Belong to first generation histamine H 1 receptor antagonist.Be mainly used in clinically alleviating allergic symptom.
At present, do not see brompheniramine at resisiting influenza virus and treat influenza infection the report that causes disease.
Summary of the invention
The object of the invention is to make up the deficiencies in the prior art, the application of a kind of micromolecular compound brompheniramine in preparation treatment or flu-prevention virus infective medicament is provided, thereby provides one micromolecular compound safely and effectively for the treatment of influenza clinically.Brompheniramine can effectively suppress copying of influenza virus within the scope of avirulence, can further be developed as the medicine for the treatment of or flu-prevention virus infection, is with a wide range of applications.
In order to prove the feasibility of brompheniramine in preparation treatment or flu-prevention virus (A type or B-mode) infection medicine, the present invention has taked following experiment to verify:
The toxicity test of brompheniramine to mdck cell: Madin-Darby canine kidney(cell line) (MDCK) is by 8 × 10
3individual cells/well is inoculated in 96 porocyte culture plates, after cell attachment, process with the brompheniramine of 0.8 μ M, 1.6 μ M, 3.125 μ M, 6.25 μ M, 12.5 μ M, 25.0 μ M, 50.0 μ M and 100.0 μ M respectively, every group is repeated two holes, is placed in 37 ℃, 5%CO
2in incubator, cultivate after 48 hours, Alamarblue detects the survival rate of cell.Result shows, the CC of brompheniramine to MDCK
50(median lethal concentration) is greater than 100.0 μ M.
The evaluation of brompheniramine anti-influenza virus activity: by mdck cell according to 1.5 × 10
4cells/well is inoculated in 96 Tissue Culture Plates, 37 ℃, 5%CO
2in cell culture incubator, cultivate.After 18-24h, use 100TCID
50virus liquid (A/PuertoRico/8/34(H1N1)) infection cell, add variable concentrations gradient medicine simultaneously.Cell is got each experimental port supernatant cultivate 48h in 37 ℃ of cell culture incubators after and is carried out the detection of neuraminic acid enzymatic activity.Result shows that brompheniramine can rely on copying of ground inhibition influenza virus, its IC by dosage
50be 14.7 μ M.
The broad spectrum activity analysis of brompheniramine resisiting influenza virus effect: by mdck cell according to 1.5 × 10
4cells/well is inoculated in 96 Tissue Culture Plates, 37 ℃, 5%CO
2in cell culture incubator, cultivate 18-24h and grow up to after monolayer, using 100TCID
50influenza virus liquid (being respectively A/human/Hubei/3/2005 (H3N2), A/WSN/S31N (H1N1), B/human/Huber/1/2007) infection cell, add the medicine of each gradient concentration simultaneously.Cell is got each experimental port supernatant after 37 ℃ of cultivation 48h and is carried out the detection of neuraminidase expression in cell culture incubator.Result shows that brompheniramine can obviously suppress copying of subtypes of influenza A virus H3N2 strain, subtypes of influenza A virus H1N1 amantadine persister and Influenza B virus, and all has dose-dependent effect.
The present invention compared with prior art, has the following advantages and effect:
1. brompheniramine is micromolecular compound, its CC
50(median lethal concentration) is greater than 100.0 μ M.Brompheniramine can copy by dose-dependent inhibition influenza virus, its IC
50(half-inhibition concentration) is 14.7 μ M.Selection index (SI) is greater than 6.8.And brompheniramine had the application of many decades clinically, safety is good.This explanation brompheniramine is the medicine of the efficient resisiting influenza virus of low toxicity.
Brompheniramine can dose-dependent inhibition subtypes of influenza A virus H3N2 strain, the copying of subtypes of influenza A virus H1N1 amantadine persister and Influenza B virus, there is the very antiviral activity of wide spectrum.
3. utilize modern common drug preparation means, can make using brompheniramine as active component any pharmaceutically acceptable dosage forms such as tablet, capsule, granule, oral liquid, slow releasing preparation, controlled release preparation, nanometer formulation or injection.
Accompanying drawing explanation
Fig. 1 is that brompheniramine cytotoxicity detects schematic diagram.
Fig. 2 is that brompheniramine treatment dosage relies on inhibition influenza virus levels of replication schematic diagram.
Fig. 3 is that brompheniramine anti-influenza virus activity broad spectrum activity detects schematic diagram, wherein:
Fig. 3 A is subtypes of influenza A virus H3N2 strain (A/human/Hubei/3/2005 (H3N2));
Fig. 3 B is subtypes of influenza A virus H1N1 amantadine persister (A/WSN/S31N (H1N1));
Fig. 3 C is Influenza B virus (B/human/Huber/1/2007).
The specific embodiment
In order to set forth better content of the present invention, below applicant in connection with specific embodiment, content of the present invention is described in further detail, but the scope of request of the present invention protection is not limited to following examples.
At present, anti-influenza virus medicament in-vitro screening model is divided into the cell free system screening model of cell culture model and viral enzyme.Enzyme reaction screening model has high-throughout feature, but the compound of screening still needs to carry out more cytology, histology and toxicity in vivo, effect experiment etc. to determine its effect.Cell culture model is the most frequently used screening model, its advantage is: can provide the identical cell of a large amount of hereditary characters to be object of study, and easy to operate, can eliminate the impact of other extraneous factor, and valid density and therapeutic index that can detection of drugs, for more how later stage mechanism research provide basis.The present invention adopts mdck cell to cultivate screening method and detects the impact that brompheniramine infected by influenza infects, the detection of the neuraminidase expression based on to representing influenza virus levels of replication in supernatant, the anti-influenza virus activity of quantitative analysis brompheniramine.
Embodiment 1: the evaluation of brompheniramine anti-influenza virus activity
1. experiment material
1.1 cells, virus and medicine
Mdck cell is purchased from US mode DSMZ (ATCC); Strain: A/PuertoRico/8/34(H1N1); Medicine: brompheniramine (CAS:86-22-6), is purchased from Sigma company.
1.2 experimental apparatus
Multiple labeling microwell plate reads instrument (Perkin Elmer).
2. experimental technique and result
2.1 cell culture: 37 ℃, 5%CO
2in humidification incubator, cultivate.The DMEM culture medium of the penicillin that use contains 10%FBS, 100U/mL and streptomycin.After cell to 90% degree of converging, go down to posterity, the ratio that goes down to posterity 1/3 – 1/4.
2.2 Virus culture: get 9～11 age in days SPF Embryo Gallus domesticus, use Egg checker inspection before virus inoculation, and at the position mark away from embryo, inoculate 2 by 0.2ml/ piece after sterilizing and punching
4the virus liquid of hemagglutinative titer, with nial polish sealing, puts 37 ℃ of calorstats and hatches after 48h(inoculation 24h dead Embryo Gallus domesticus to be generally misoperation lethal, abandons it).Take out Embryo Gallus domesticus and put 4 ℃ of cold embryo 12h.75% alcohol disinfecting chick embryo air sac, sterile working cuts off air chamber shell, and capillary pipette is drawn chick embryo allantoic liquid and amniotic fluid, and 3000rpm4 ℃ of centrifugal 30min detects hemagglutinative titer, and 200 μ l/ pipe subpackage juxtaposition-70 are ℃ frozen for subsequent use.
The cytotoxicity of 2.3 brompheniramine detects: mdck cell is by 8 × 10
3(100 μ l) are inoculated in 96 porocyte culture plates cells/well, for subsequent use after cell attachment; With cell maintenance medium (DMEM+2% serum), medicine is amounted to 6 gradients take 100.0 μ M as maximum concentration according to 2 gradient dilutions and process, 2 multiple holes of every gradient.After cultivating 48h, discard culture supernatant, the new DMEM culture medium that adds 100 μ l to contain 10%Alamarblue reagent in every hole, puts in cell culture incubator and continues to cultivate 1h, after 1h, measures respectively fluorescence and light absorption value with multi-tester, calculates cell survival rate.
Result shows that (Fig. 1) brompheniramine does not have cytotoxicity completely to mdck cell within the scope of 100.0 μ M, illustrates that brompheniramine has the safer scope of application, and the dosage of brompheniramine is 0.0～100.0 μ M according to cell experiment consumption.
The antiviral activity evaluation of 2.4 brompheniramine infected by influenza strain A/PuertoRico/8/34 (H1N1)
2.4.1. experimental principle: MUNANA(4-methylumbelliferyl-α-N-acetyl-neuraminate) be the specific substrate of influenza neuraminidase, the catalysate producing under neuraminidase effect is under 355nm excitation light irradiation, can produce 460nm fluorescence, the power of fluorescence intensity has represented the number of viral neuraminidase expression, has reflected the virus quantity in cultured cell supernatant.
2.4.2. mdck cell is pressed to 1.5 × 10
4cells/well is inoculated in 96 porocyte culture plates, in 37 ℃ of cell culture incubators, cultivates after 14～18h, for subsequent use after cell grows up to monolayer.Culture medium in orifice plate is discarded, and PBS cleans after twice, adds 100TCID
50(l) (100 μ l) cultivate 100 μ virus liquid in 37 ℃ of cell culture incubators with variable concentrations medicine.Medicine is take 100.0 μ M as initial concentration, 6 gradients of continuous 2 times of gradient dilutions, and every gradient arranges two multiple holes.After cultivation 48h, get each experimental port supernatant and carry out the detection of neuraminic acid enzymatic activity.Experiment arranges blank group, positive controls (ribavirin), negative control group (after viral infection without drug treating) and Experimental agents group.
2.4.3. in black 96 hole micro plates, add 40 μ l buffer (32.5mmol/L MES, pH6.5,4mmol/LCaCl
2) preparation substrate 20umol/L MUNANA, add again each experimental port culture supernatant 20 μ l, 37 ℃ of lucifuges are hatched 60min, add reaction terminating liquid (0.014 μ M NaOH, 83% ethanol) 100 μ l/ holes, micropore reads to measure on plate instrument fluorescent value (excitation wavelength 355nm, wavelength of transmitted light 465nm).
2.4.4. calculate the suppression ratio that each detection hole Chinese medicine infected by influenza copies.
Suppression ratio (%)=100-(sample well-blank)/(enzyme contrast-blank alive) * 100%
Result shows: along with the increase of brompheniramine drug level, the suppression ratio that medicine infected by influenza copies raises gradually, and the dosage presenting clearly relies on effect.It can suppress 50% virus replication in 14.7 μ M concentration, and selection index is greater than 6.8, in the time of 50.0 μ M concentration, reaches and approaches 100% suppression ratio.(seeing Fig. 2).
Embodiment 2: the evaluation of brompheniramine resisiting influenza virus effect broad spectrum activity
On the basis of embodiment 1, the present embodiment has further detected the antiviral activity of brompheniramine to subtypes of influenza A virus H3N2 strain, subtypes of influenza A virus H1N1 amantadine persister and Influenza B virus.
1. experiment is used Strain to comprise: A/human/Hubei/3/2005 (H3N2), A/WSN/S31N (H1N1), B/human/Huber/1/2007
2. mdck cell is pressed to 1.5 × 10
4cells/well is inoculated in 96 porocyte culture plates, in 37 ℃ of cell culture incubators, cultivates after 14～18h, for subsequent use after cell grows up to monolayer.Culture medium in orifice plate is discarded, and PBS cleans after twice, adds 100TCID
50(l) (100 μ l) cultivate 100 μ virus liquid in 37 ℃ of cell culture incubators with variable concentrations medicine.Medicine is take 100.0 μ M as initial concentration, 6 gradients of continuous 2 times of gradient dilutions, and every gradient arranges two multiple holes.After cultivation 48h, get each experimental port supernatant and carry out the detection of neuraminic acid enzymatic activity.
3. in black 96 hole micro plates, add 40 μ l buffer (32.5mmol/L MES, pH6.5,4mmol/LCaCl
2) preparation substrate 20umol/L MUNANA, add again each experimental port culture supernatant 20 μ l, 37 ℃ of lucifuges are hatched 60min, add reaction terminating liquid (0.014 μ M NaOH, 83% ethanol) 100 μ l/ holes, on multi-tester, measure fluorescent value (excitation wavelength 355nm, wavelength of transmitted light 465nm).
4. calculate the suppressed rate of neuraminidase in each detection hole.
Suppression ratio (%)=100-(sample well-blank)/(enzyme contrast-blank alive) * 100%
Result shows that brompheniramine has obviously suppressed copying of various influenza virus strains within the scope of drug level, and is all dose-dependence (see figure 3).Its half-inhibition concentration (IC to influenza A virus H3N2, influenza A virus amantadine persister and Influenza B virus
50) being respectively 16.3 μ M, 28.4 μ M and 12.5 μ M, corresponding selection index is greater than respectively 6.1,3.5 and 8.0.Show that brompheniramine is a kind of anti-influenza virus medicament of wide spectrum.
Claims (7)
1. the application of brompheniramine in preparation treatment or flu-prevention virus infective medicament.
2. application as claimed in claim 1, is characterized in that: described influenza virus is influenza A virus or Influenza B virus.
3. application as claimed in claim 1, is characterized in that: described medicine is using brompheniramine or its various salt forms as active constituents of medicine.
4. application as claimed in claim 1, is characterized in that: described medicine is oral administered dosage form, injecting medicine-feeding form, mucosa delivery dosage form or percutaneous dosing dosage form.
5. application as claimed in claim 1, is characterized in that: described medicine is any pharmaceutically acceptable dosage form.
6. application as claimed in claim 5, is characterized in that: described medicine is tablet, capsule, granule, oral liquid or injection.
7. application as claimed in claim 5, is characterized in that: described medicine is slow releasing preparation, controlled release preparation or nanometer formulation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410157329.9A CN103893175A (en) | 2014-04-18 | 2014-04-18 | Application of brompheniramine in preparation of medicine for treating or preventing influenza virus infection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410157329.9A CN103893175A (en) | 2014-04-18 | 2014-04-18 | Application of brompheniramine in preparation of medicine for treating or preventing influenza virus infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103893175A true CN103893175A (en) | 2014-07-02 |
Family
ID=50984967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410157329.9A Pending CN103893175A (en) | 2014-04-18 | 2014-04-18 | Application of brompheniramine in preparation of medicine for treating or preventing influenza virus infection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103893175A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111000844A (en) * | 2019-12-19 | 2020-04-14 | 浙江立恩生物科技有限公司 | Medicine for treating influenza virus infection |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103239446A (en) * | 2013-05-13 | 2013-08-14 | 中国科学院武汉病毒研究所 | Application of chlorpheniramine maleate in preparation of medicaments for treating or preventing influenza virus |
-
2014
- 2014-04-18 CN CN201410157329.9A patent/CN103893175A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103239446A (en) * | 2013-05-13 | 2013-08-14 | 中国科学院武汉病毒研究所 | Application of chlorpheniramine maleate in preparation of medicaments for treating or preventing influenza virus |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111000844A (en) * | 2019-12-19 | 2020-04-14 | 浙江立恩生物科技有限公司 | Medicine for treating influenza virus infection |
| CN111000844B (en) * | 2019-12-19 | 2022-06-28 | 浙江立恩生物科技有限公司 | Medicine for treating influenza virus infection |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102257135A (en) | Production of viral vaccine | |
| CN103893171B (en) | The application of benzydamine hydrochloride in preparation treatment or flu-prevention virus infective medicament | |
| CN103690536A (en) | Application of ciclopirox olamine in preparing medicine for treating or preventing influenza virus infection | |
| CN103705506B (en) | Application of enilconazole in preparing drug for treating or preventing influenza virus infections | |
| CN103705497B (en) | Application of liothyronine in preparation of medicine for treatment or prevention of influenza virus infection | |
| CN103720687B (en) | The application of dicoumarol in the medicine preparing treatment or flu-prevention viral infection | |
| CN103239446B (en) | Application of chlorpheniramine maleate in preparation of medicaments for treating or preventing influenza virus | |
| CN103893187B (en) | The application of trimeprimine in preparation treatment or flu-prevention virus infective medicament | |
| CN103720684B (en) | The application of bentrl hydrothloride in preparation treatment or flu-prevention virus infective medicament | |
| CN103614345A (en) | Influenza virus vaccine strain | |
| CN103690517B (en) | Application of dithranol to preparation of medicament for treating or preventing influenza virus infection | |
| CN103705516B (en) | The application of chloroxine in the medicine preparing treatment or flu-prevention viral infection | |
| CN103893175A (en) | Application of brompheniramine in preparation of medicine for treating or preventing influenza virus infection | |
| CN103705498A (en) | Application of fenofibrate in preparing drug for treating or preventing influenza virus infections | |
| CN103893162B (en) | The application of proadifen in preparation treatment or flu-prevention virus infective medicament | |
| CN103705522B (en) | Application of promethazine hydrochlorine in preparation of drug for treatment or prevention of influenza virus infection | |
| CN103251576B (en) | Application of diphenhydramine hydrochloride in preparation of medicines for treating or preventing influenza viruses | |
| CN109453174B (en) | Application of effective inhibitor of type III phosphatidylinositol phosphokinase in preparation of medicine for treating or preventing influenza virus infection | |
| Bhalerao et al. | An Updated Review on Influenza Viruses | |
| CN103690522B (en) | Application of nafronyloxalate in preparing medicine for treating or preventing influenza virus | |
| CN103877068A (en) | Application of diethylstilbestrol to preparation of medicine for treating or preventing influenza virus infection | |
| CN103251590B (en) | Application of doxylamine succinate in preparing drug for treating or preventing influenza virus | |
| CN108721264B (en) | Application of isoxsuprine in preparing medicine for treating or preventing influenza virus infection | |
| CN103251591B (en) | Application of mepyramine maleate in preparing drug for treating or preventing influenza virus | |
| CN107286044A (en) | It is a kind of to suppress the compound that influenza virus PB2 albumen is combined with RNA caps |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140702 |